KEEP Labs Inc. | January 28, 2022
KEEP Labs, the Modern Medicine Cabinet and KARE by KEEP Adherence Platform developers, are pleased to announce a partnership with McKesson Canada to provide a novel solution for Canadians taking specialty medications.
A majority of healthcare activities occur in the home, making it a critical place to monitor, engage and support patients. KEEP's state of the art technology and intuitive design allows McKesson Canada to provide an award-winning adherence platform that supports all dosage forms, from oral to injectable therapies. This partnership extends the reach of McKesson Canada's patient engagement capabilities, allowing them to gain greater insight into how to best support patients in real-time.
KEEP and McKesson Canada are building the patient experience of the future. Despite notable advancements in new treatment options, adherence rates remain stagnant. Patient support programs have an opportunity to expand their services to drive adherence, capture real world evidence (RWE) and utilize new data sources to intelligently guide which patients can benefit most from specific interventions.
"A key function of KEEP is removing friction throughout the entire patient journey and passively capturing daily dosing events through automation in real-time, rather than relying on patients to manually input when doses are taken. When we have full visibility to the last and most important mile of the therapy journey, we have the best opportunity to intervene in a proactive and meaningful way. We're helping to enable the industry to transition from retrospective monthly data points to real-time and actionable intervention capabilities."
Jeff Wandzura, RPh, CEO of KEEP Labs
KEEP has built an integrated technology ecosystem to support providers with the data they need to make informed decisions. Patient support program providers are confronting the complexity of integrating disparate systems to deliver actionable intelligence to all stakeholders. McKesson Canada's commitment to providing an industry-leading technology stack starts by ensuring that innovative partners, like KEEP, are enhancing and complementing existing technologies through seamless integration.
The ability to intervene in real-time via nurse outreach, educational content or behavioural nudges that are configured on a program and patient archetype specific basis allows McKesson Canada to personalize the experience for each patient. These learnings are continually refined over the course of the program (using real world data), providing a first-of-its-kind data set with outcomes reported to partner organizations and members of the care team.
ABOUT KEEP LABS
KEEP Labs is a Canadian tech company founded by two dads who were looking for a smart way to store prescription medication at home. KEEP Lab's introductory product, KEEP, is a TIME Best Invention of 2020 and CES 2020 Innovation Honoree. KARE by KEEP is the first medication adherence and analytics platform for global life sciences companies, patient support programs and pharmacy networks that integrates both hardware and software for all dosage forms, providing deeper insight into the patient journey at home.
Phio Pharmaceuticals Corp | October 26, 2020
Phio Pharmaceuticals Corp. a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020.
Pfizer | December 21, 2020
Since the time Pfizer was fixed to partake in the U.S. government's Warp Speed exertion to get COVID-19 antibodies to showcase, the organization has made it very clear it didn't have to take any bureaucratic cash to build up the immunization.
In any case, did that refusal of R&D subsidizing add to Pfizer's failure to produce more dosages of its mRNA antibody for the U.S. market?
Pfizer could give more than the 100 million portions it guaranteed in its unique agreement with the U.S. government in the main portion of one year from now—however just if Trump organization authorities request that providers of crude materials rapidly satisfy the organization's requests. Furthermore, CEO Albert Bourla, Ph.D., is approaching the public authority to utilize the Defense Production Act to do precisely that.
The Trump organization hasn't done as such yet on the grounds that they've zeroed in on giving those materials to antibody producers that took government R&D subsidizing, as Moderna, as indicated by anonymous sources who addressed The New York Times.
A representative for Pfizer declined to remark, refering to the privacy of conversations with the U.S. government. Yet, Bourla said during a CNBC meet that the organization is in exchanges to sell an extra 100 million dosages of Pfizer's COVID-19 immunization to the U.S. government.
"We can give a ton of that in the second from last quarter. The U.S. government needs it in the subsequent quarter," Bourla said in the Monday meet. "We are working cooperatively to attempt to discover an answer and have the option to apportion those 100 million [doses] in the subsequent quarter if conceivable, or a ton of them."
Pfizer mentioned almost immediately that the public authority grant it "supported status" with providers of crude materials, however authorities were anxious about the possibility that that would harm contending immunization programs that took government R&D cash, as per the Times report. Among those organizations is Moderna, which is required to win crisis use approval from the FDA for its mRNA immunization this week—and last Friday, inked an arrangement to add 100 million additional portions to its underlying U.S. request.